A small biotech company, BioCryst Pharmaceuticals was founded in Birmingham, Alabama. BioCryst is a pharmaceutical company that has stayed true to its commitment to discovering, developing, and delivering treatments to patients that may have an extraordinary impact on their lives. BioCryst Pharmaceuticals specialize in structure-guided small molecule drug design, using detailed knowledge of the structures of active sites of clinically significant enzymes to develop novel agents which interfere with the progression of the disease. Founded in 1986, the company’s development pipeline currently includes inhibitor-based treatment programs for hereditary angioedema (HAE), hemorrhagic fevers, influenza and gout.
Quotient Sciences were approached to help BioCryst Pharmaceuticals in their development of BCX4161, a promising candidate for the treatment of hereditary angioedema. They took advantage of our Translational Pharmaceutics® platform and First-In-Human program for the development to accelerate their timelines and hit key deadlines. Request a copy of the case study today here.
Learn more about how Quotient Sciences' experts helped BioCryst Pharmaceuticals with the development of BCX4161, a candidate for the treatment of hereditary angioedema (HAE).
"Quotient Sciences' real-time manufacturing capabilities were a key factor in determining the speed at which this study could be concluded, offering the rare combination of GMP manufacturing and clinical administration on the same site, even for complex formulations and dosage forms."
- Dr. Phil Collis, Vice President of Clinical Development at BioCryst Pharmaceuticals